MX2016017257A - Farmaceuticos para el tratamiento de mareo que tiene diferentes causas. - Google Patents
Farmaceuticos para el tratamiento de mareo que tiene diferentes causas.Info
- Publication number
- MX2016017257A MX2016017257A MX2016017257A MX2016017257A MX2016017257A MX 2016017257 A MX2016017257 A MX 2016017257A MX 2016017257 A MX2016017257 A MX 2016017257A MX 2016017257 A MX2016017257 A MX 2016017257A MX 2016017257 A MX2016017257 A MX 2016017257A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- active ingredient
- way
- pharmaceutical
- dimensionally stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con una forma de dosificación, que comprende: ? un ingrediente activo o un derivado, sal y/o profármaco del mismo, ? una porción dimensionalmente estable que no se disuelve en un medio acuoso a un valor de pH de < 5 durante un periodo de tiempo de 2 horas también bajo estas condiciones a un grado que su diámetro más pequeño disminuye a un valor de < 5 mm, ? una porción que es soluble en el jugo gástrico que se disuelve en un medio acuoso a un valor de pH <5 durante un periodo de tiempo menor de 2 horas o que se erosiona bajo estas condiciones a un grado que su diámetro más largo disminuye a un valor de < 2 mm, en donde la porción dimensionalmente estable y también la porción que es soluble en el jugo gástrico contienen una cantidad parcial del ingrediente activo, para el uso en un método para el tratamiento de mareo en humanos mediante la administración a un paciente con o después de una comida a lo más dos veces al día.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14174604.0A EP2959887B1 (de) | 2014-06-26 | 2014-06-26 | Arzneimittel zur Behandlung von Schwindel verschiedener Genese |
PCT/EP2015/064560 WO2015197833A1 (de) | 2014-06-26 | 2015-06-26 | Arzneimittel zur behandlung von schwindel verschiedener genese |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016017257A true MX2016017257A (es) | 2017-04-10 |
Family
ID=50981430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016017257A MX2016017257A (es) | 2014-06-26 | 2015-06-26 | Farmaceuticos para el tratamiento de mareo que tiene diferentes causas. |
Country Status (19)
Country | Link |
---|---|
US (1) | US10471056B2 (es) |
EP (1) | EP2959887B1 (es) |
KR (2) | KR20170021344A (es) |
AU (1) | AU2015279099B2 (es) |
CA (1) | CA2952747C (es) |
EA (1) | EA035422B1 (es) |
ES (1) | ES2720731T3 (es) |
HR (1) | HRP20190230T1 (es) |
HU (1) | HUE043399T2 (es) |
IL (1) | IL249743B (es) |
LT (1) | LT2959887T (es) |
MX (1) | MX2016017257A (es) |
PH (1) | PH12016502591B1 (es) |
PL (1) | PL2959887T3 (es) |
PT (1) | PT2959887T (es) |
SI (1) | SI2959887T1 (es) |
UA (1) | UA123042C2 (es) |
WO (1) | WO2015197833A1 (es) |
ZA (1) | ZA201700112B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200015242A (ko) | 2018-08-03 | 2020-02-12 | 주식회사 아이더블류솔루션 | 맞춤형 업체 매칭 및 거래 정보 시각화 시스템 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922352A (en) * | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
DE102005014141B4 (de) * | 2005-03-23 | 2006-12-21 | Hennig Arzneimittel Gmbh & Co. Kg | Tablettenförmige Retardzubereitung gegen Schwindel |
DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
JP2007036385A (ja) * | 2005-07-22 | 2007-02-08 | Fujitsu Ltd | 無線通信におけるパケットスケジューリング方法及び装置 |
US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
WO2011082426A1 (en) * | 2010-01-04 | 2011-07-07 | Eurand, Inc. | Controlled release compositions comprising meclizine or related piperazine derivatives |
ES2755075T3 (es) | 2011-05-05 | 2020-04-21 | Hennig Arzneimittel Gmbh&Co Kg | Forma farmacológica para la liberación dirigida de principios activos |
DE102011051304A1 (de) | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Wirkstoffmatrix |
DE102011051308A1 (de) | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Herstellungsverfahren und Arzneiform |
DE102011053068A1 (de) | 2011-08-29 | 2013-02-28 | Hennig Arzneimittel Gmbh & Co. Kg | Darreichungsform mit stabilisierten Wirkstoffpartikeln |
DE102012105512A1 (de) | 2012-06-25 | 2014-04-24 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur verlängerten Freisetzung von Wirkstoffen |
SI2938328T1 (sl) * | 2012-12-27 | 2023-11-30 | Hennig Arzneimittel Gmbh & Co. Kg | Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin |
-
2014
- 2014-06-26 PT PT14174604T patent/PT2959887T/pt unknown
- 2014-06-26 EP EP14174604.0A patent/EP2959887B1/de active Active
- 2014-06-26 HU HUE14174604A patent/HUE043399T2/hu unknown
- 2014-06-26 ES ES14174604T patent/ES2720731T3/es active Active
- 2014-06-26 LT LTEP14174604.0T patent/LT2959887T/lt unknown
- 2014-06-26 SI SI201431037T patent/SI2959887T1/sl unknown
- 2014-06-26 PL PL14174604T patent/PL2959887T3/pl unknown
-
2015
- 2015-06-26 KR KR1020177002511A patent/KR20170021344A/ko active Application Filing
- 2015-06-26 AU AU2015279099A patent/AU2015279099B2/en active Active
- 2015-06-26 UA UAA201700680A patent/UA123042C2/uk unknown
- 2015-06-26 KR KR1020237013090A patent/KR20230054775A/ko not_active Application Discontinuation
- 2015-06-26 MX MX2016017257A patent/MX2016017257A/es active IP Right Grant
- 2015-06-26 CA CA2952747A patent/CA2952747C/en active Active
- 2015-06-26 WO PCT/EP2015/064560 patent/WO2015197833A1/de active Application Filing
- 2015-06-26 US US15/322,092 patent/US10471056B2/en active Active
- 2015-06-26 EA EA201790089A patent/EA035422B1/ru unknown
-
2016
- 2016-12-22 PH PH12016502591A patent/PH12016502591B1/en unknown
- 2016-12-23 IL IL249743A patent/IL249743B/en active IP Right Grant
-
2017
- 2017-01-05 ZA ZA2017/00112A patent/ZA201700112B/en unknown
-
2019
- 2019-02-05 HR HRP20190230TT patent/HRP20190230T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230054775A (ko) | 2023-04-25 |
EP2959887A1 (de) | 2015-12-30 |
PT2959887T (pt) | 2019-02-04 |
LT2959887T (lt) | 2019-03-12 |
WO2015197833A1 (de) | 2015-12-30 |
US20170128441A1 (en) | 2017-05-11 |
ES2720731T3 (es) | 2019-07-24 |
CA2952747A1 (en) | 2015-12-30 |
SI2959887T1 (sl) | 2019-04-30 |
KR20170021344A (ko) | 2017-02-27 |
AU2015279099B2 (en) | 2019-10-31 |
IL249743A0 (en) | 2017-02-28 |
HUE043399T2 (hu) | 2019-08-28 |
EP2959887B1 (de) | 2018-11-14 |
HRP20190230T1 (hr) | 2019-03-22 |
CA2952747C (en) | 2021-04-27 |
AU2015279099A1 (en) | 2017-01-19 |
US10471056B2 (en) | 2019-11-12 |
PH12016502591A1 (en) | 2017-04-24 |
PH12016502591B1 (en) | 2017-04-24 |
UA123042C2 (uk) | 2021-02-10 |
EA035422B1 (ru) | 2020-06-11 |
EA201790089A1 (ru) | 2017-05-31 |
ZA201700112B (en) | 2018-11-28 |
IL249743B (en) | 2020-08-31 |
PL2959887T3 (pl) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
CY1124104T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
IN2013MU03583A (es) | ||
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
PH12018500814A1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
MX2022013450A (es) | Formulaciones farmaceuticas. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
PH12016502591A1 (en) | Pharmaceutical for treating dizziness having different causes | |
WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
MX2018010065A (es) | Forma de dosificacion oral que comprende rifaximina en forma beta. | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
MX2019008847A (es) | Profarmacos de cisteamina. | |
MX2019001190A (es) | Composicion de liberacion sostenida que comprende tolcapona micronizada. | |
MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
EA201691599A1 (ru) | Комбинация таурина и рацеметионина для лечения заболеваний печени | |
MX2018004776A (es) | Compuestos oxaazaespiricos con actividad contral el dolor. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |